BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...its first chief commercial officer. He was VP of business development and strategic planning at Durect Corp....
BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...for an advisory committee meeting to review the oral FXR agonist. FDA panel split on Durect...
...Thursday on the question of whether the risk-benefit profile of Posimir bupivacaine extended-release solution from Durect Corp....
...NN9535 (Compound #), subcutaneous semaglutide (Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent...
BioCentury | Jan 14, 2020
Company News

Amid need for new pain options, FDA panel rebuffs Nektar’s ‘safer’ opioid

...from Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI) Wednesday, and an extended-release bupivacaine for post-surgical analgesia from Durect Corp....
BioCentury | Jan 2, 2020
Clinical News

Durect looks ahead to liver indications after Phase IIa miss in psoriasis

...of topical DUR-928 in a Phase IIa psoriasis trial vaporized more than a quarter of Durect’s...
...studies of injectable and oral versions of the therapy to treat alcoholic hepatitis and NASH. Durect Corp....
...28 days. Durect will no longer develop the topical formulation for psoriasis. The news drove Durect...
BioCentury | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

...date of Jan. 16 to discuss an NDA submission for Posimir bupivacaine extended-release solution from Durect Corp....
...been assigned. Jonathan Block and Paul Bonanos, Associate Editors Keytruda, pembrolizumab (MK-3475, lambrolizumab) Merck & Co. Inc. Roivant Sciences Ltd. Durect Corp. PureTech...
BioCentury | Jul 22, 2019
Clinical News

Gilead moving forward with long-acting HIV treatments

...for treatment-experienced people living with multidrug resistant HIV. The company also entered a deal with Durect...
...cells resistant to GS-6207 were not resistant to other classes of antiretrovirals. Also on Monday, Durect Corp....
...said it granted Gilead exclusive, worldwide rights to develop a long-acting, injectable HIV product using Durect's...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...whose cancer has progressed after platinum-based chemotherapy and at least one other line of treatment Durect Corp....
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...science and of biological pharmaceutical development at Sanofi (Euronext:SAN; NYSE:SNY). Epigenetics and drug delivery company Durect Corp....
BioCentury | Aug 10, 2018
Clinical News

Pain shifting to AD following fourth Remoxy CRL

...abuse-deterrence technology from partner Durect Corp. (NASDAQ:DRRX). Durect was up $0.03 to $1.44 on Aug. 6. Durect Corp....
...Product: Remoxy ER oxycodone extended release (PF-00345439) Business: Neurology Sandi Wong PTI-125 PTI-125DX Remoxy ER, oxycodone extended release (PF-00345439, PTI-821) Durect Corp. Pain...
BioCentury | Aug 6, 2018
Company News

Pain shifting to AD following fourth Remoxy CRL

...a high-viscosity capsule formulation of oxycodone that uses Oradur abuse-deterrence technology from partner Durect Corp. (NASDAQ:DRRX). Durect...
...NASDAQ:DRRX). Durect was up $0.03 to $1.44 on Monday. Sandi Wong Remoxy ER, oxycodone extended release (PF-00345439, PTI-821) Durect Corp. Pain...
Items per page:
1 - 10 of 354
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...its first chief commercial officer. He was VP of business development and strategic planning at Durect Corp....
BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...for an advisory committee meeting to review the oral FXR agonist. FDA panel split on Durect...
...Thursday on the question of whether the risk-benefit profile of Posimir bupivacaine extended-release solution from Durect Corp....
...NN9535 (Compound #), subcutaneous semaglutide (Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent...
BioCentury | Jan 14, 2020
Company News

Amid need for new pain options, FDA panel rebuffs Nektar’s ‘safer’ opioid

...from Intellipharmaceutics International Inc. (TSX:IPCI; NASDAQ:IPCI) Wednesday, and an extended-release bupivacaine for post-surgical analgesia from Durect Corp....
BioCentury | Jan 2, 2020
Clinical News

Durect looks ahead to liver indications after Phase IIa miss in psoriasis

...of topical DUR-928 in a Phase IIa psoriasis trial vaporized more than a quarter of Durect’s...
...studies of injectable and oral versions of the therapy to treat alcoholic hepatitis and NASH. Durect Corp....
...28 days. Durect will no longer develop the topical formulation for psoriasis. The news drove Durect...
BioCentury | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

...date of Jan. 16 to discuss an NDA submission for Posimir bupivacaine extended-release solution from Durect Corp....
...been assigned. Jonathan Block and Paul Bonanos, Associate Editors Keytruda, pembrolizumab (MK-3475, lambrolizumab) Merck & Co. Inc. Roivant Sciences Ltd. Durect Corp. PureTech...
BioCentury | Jul 22, 2019
Clinical News

Gilead moving forward with long-acting HIV treatments

...for treatment-experienced people living with multidrug resistant HIV. The company also entered a deal with Durect...
...cells resistant to GS-6207 were not resistant to other classes of antiretrovirals. Also on Monday, Durect Corp....
...said it granted Gilead exclusive, worldwide rights to develop a long-acting, injectable HIV product using Durect's...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...whose cancer has progressed after platinum-based chemotherapy and at least one other line of treatment Durect Corp....
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...science and of biological pharmaceutical development at Sanofi (Euronext:SAN; NYSE:SNY). Epigenetics and drug delivery company Durect Corp....
BioCentury | Aug 10, 2018
Clinical News

Pain shifting to AD following fourth Remoxy CRL

...abuse-deterrence technology from partner Durect Corp. (NASDAQ:DRRX). Durect was up $0.03 to $1.44 on Aug. 6. Durect Corp....
...Product: Remoxy ER oxycodone extended release (PF-00345439) Business: Neurology Sandi Wong PTI-125 PTI-125DX Remoxy ER, oxycodone extended release (PF-00345439, PTI-821) Durect Corp. Pain...
BioCentury | Aug 6, 2018
Company News

Pain shifting to AD following fourth Remoxy CRL

...a high-viscosity capsule formulation of oxycodone that uses Oradur abuse-deterrence technology from partner Durect Corp. (NASDAQ:DRRX). Durect...
...NASDAQ:DRRX). Durect was up $0.03 to $1.44 on Monday. Sandi Wong Remoxy ER, oxycodone extended release (PF-00345439, PTI-821) Durect Corp. Pain...
Items per page:
1 - 10 of 354